



This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|-----------------------------|---|--|--|--|
| Endocrine/metabolic disease | | | | |
| Diabetes | Inositol 1,4,5-triphosphate receptor (ITPR; IP3R) | Mouse studies suggest inhibiting IP3R could help treat diabetes. In normal mice, RNAi against <i>Ip3r</i> lowered the expression of gluconeogenic genes and circulating glucose concentrations compared with scrambled RNAi. In a mouse model of diabetes, RNAi against <i>Ip3r</i> decreased gluconeogenic gene expression and hepatic gluconeogenesis compared with nontargeting RNAi. Next steps could include screening for small molecule inhibitors of IP3R. | Patent and licensing status unavailable | Wang, Y. et al. Nature; published online April 8, 2012; doi:10.1038/nature10988 Contact: Marc Montminy, The Salk Institute for Biological Studies, La Jolla, Calif. e-mail: montminy@salk.edu |
| | | SciBX 5(17); doi:10.1038/scibx.2012.440 Published online April 26, 2012 | | |